Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Capital Expenditures (2016 - 2026)

Champions Oncology has reported Capital Expenditures over the past 17 years, most recently at $172000.0 for Q1 2026.

  • Quarterly results put Capital Expenditures at $172000.0 for Q1 2026, down 59.81% from a year ago — trailing twelve months through Jan 2026 was $156000.0 (down 87.66% YoY), and the annual figure for FY2025 was $389000.0, down 53.47%.
  • Capital Expenditures for Q1 2026 was $172000.0 at Champions Oncology, up from -$263000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for CSBR hit a ceiling of $836000.0 in Q2 2024 and a floor of -$747000.0 in Q1 2024.
  • Median Capital Expenditures over the past 5 years was $428000.0 (2025), compared with a mean of $346866.7.
  • Biggest five-year swings in Capital Expenditures: plummeted 199.07% in 2024 and later skyrocketed 157.3% in 2025.
  • Champions Oncology's Capital Expenditures stood at $604000.0 in 2022, then tumbled by 86.92% to $79000.0 in 2023, then skyrocketed by 958.23% to $836000.0 in 2024, then crashed by 131.46% to -$263000.0 in 2025, then soared by 165.4% to $172000.0 in 2026.
  • The last three reported values for Capital Expenditures were $172000.0 (Q1 2026), -$263000.0 (Q4 2025), and $286000.0 (Q3 2025) per Business Quant data.